SFARI 2022 Human Cognitive and Behavioral Science RFA: Informational session
On February 25, 2022, SFARI held an informational session about the 2022 Human Cognitive and Behavioral Science request for applications. The session provided an overview of the RFA and its scientific priorities from SFARI senior scientist Pamela Feliciano, SFARI clinical research scientist LeeAnne Green Snyder, SFARI senior scientist Alice Luo Clayton and Clinical Research Associates deputy director Paul Wang.
SFARI 2022 Bridge to Independence Award RFA: Informational session
SFARI hosted an informational session on the 2022 Bridge to Independence Award (BTI) request for applications (RFA). The session provided a brief overview of the BTI program and its objectives from SFARI senior scientist Alice Luo Clayton and an open Q&A panel and breakout room discussions with current BTI fellows Gabriella Boulting, Marino Pagan, and Stephanie Rudolph.
Autism Rat Models Consortium RFA: Informational session
On July 26, SFARI hosted an informational session on the Autism Rat Models Consortium request for applications (RFA). SFARI senior scientist Alice Luo Clayton, and Peter Kind, director of the Simons Initiative for the Developing Brain (SIDB) at the University of Edinburgh will present the goals and objectives of this new funding opportunity and be available to answer questions from potential applicants.
What do we mean by ‘autism risk genes’?
Chief Clinical Officer, Dascena
Joseph Buxbaum, Ph.D.
Director, Seaver Autism Center
Professor, Psychiatry, Neuroscience, Genetics and Genomic Sciences
Vice Chair for Research and Vice Chair for Mentoring, Psychiatry, Icahn School of Medicine at Mount Sinai
Heather Mefford, M.D., Ph.D.
Full Member, St. Jude Children’s Research Hospital
David Ledbetter and Joseph Buxbaum discussed whether there are genes for which mutations confer risk specific to autism or whether these genes are really conferring general risk of disrupted brain development. The discussion was moderated by Heather Mefford.
SFARI 2021 Genomics of ASD: Pathways to Genetic Therapies RFA — Informational session
The SFARI science team held an informational session to answer questions about the 2021 Genomics of ASD: Pathways to Genetic Therapies request for applications.
Small molecules, genes and antisense oligonucleotides: Industry perspectives on treatment development for ASD
Vice President, Head of Clinical Science, Axial Therapeutics
Stuart Cobb, Ph.D.
Chief Scientific Officer, Neurogene; Research Fellow, University of Edinburgh
Yael Weiss, M.D., Ph.D.
Vice President, Business Development, Ultragenyx
Randy Carpenter, M.D.
Chief Medical Officer, Rett Syndrome Research Trust; Co-Founder, Allos Pharma
Federico Bolognani, Stuart Cobb, and Yael Weiss joined a panel to discuss new industry developments on the use of small molecules, gene therapy and antisense oligonucleotides as treatment approaches for autism spectrum disorders (ASD). The panel discussion was moderated by Randall Carpenter.
- Previous Page
- Next Page